Oral Solid Dosage Pharmaceutical Formulation Market Growth Outlook Through 2024-2033

Global oral solid dosage pharmaceutical formulation market size is expected to reach $792.37 Bn by 2028 at a rate of 6.4%, segmented as by dosage form, tablets, capsules, powders and granules, lozenges and pastilles, gummies

Jun 28, 2024 - 16:28

0 7

Oral Solid Dosage Pharmaceutical Formulation Market Growth Outlook Through 2024-2033

Overview and Scope
Oral solid dosage pharmaceutical formulation refers to a type of medication administered orally in a solid form. These formulations are designed to be swallowed and then dissolved or dispersed in the gastrointestinal tract, where the active pharmaceutical ingredients (APIs) are absorbed into the bloodstream to exert their therapeutic effects. Oral solid dosage pharmaceutical formulations are a cornerstone of modern medicine, offering a reliable, convenient, and effective method for drug delivery.

Sizing and Forecast
The oral solid dosage pharmaceutical formulation market size has grown strongly in recent years. It will grow from $583.07 billion in 2023 to $618.34 billion in 2024 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to chronic disease prevalence, aging population, healthcare access expansion, generic formulation promotion, and consumer preference shift.

The oral solid dosage pharmaceutical formulation market size is expected to see strong growth in the next few years. It will grow to $792.37 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to personalized medicine demand, controlled-release adoption, biopharmaceutical focus, emerging market expansion, and policy and reimbursement changes. Major trends in the forecast period include personalized medicine adoption, digital health integration, the rise of telemedicine services, focus on preventive healthcare, and continued expansion of artificial intelligence in healthcare.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-pharmaceutical-formulation-global-market-report

Segmentation & Regional Insights
The oral solid dosage pharmaceutical formulation market covered in this report is segmented –

1) By Dosage Form: Tablets, Capsules, Powders And Granules, Lozenges And Pastilles, Gummies
2) By Mechanism: Controlled-Release, Immediate-Release, Delayed-Release
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies, Hypermarkets Or Supermarkets
4) By End-User: Large-Size Companies, Medium And Small-Size Companies, Other End-Users

North America was the largest region in the oral solid dosage pharmaceutical formulation market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral solid dosage pharmaceutical formulation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15626&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of chronic diseases is expected to propel the growth of the oral solid dosage pharmaceutical formulation market going forward. Chronic diseases refer to long-term health conditions that persist for an extended period, typically lasting for three months or more. Chronic diseases is rising due to factors such as aging populations, sedentary lifestyles, poor dietary habits, environmental factors, and improved detection and diagnosis methods. Oral solid dosage pharmaceutical formulations are integral to chronic disease management and support long-term treatment adherence, as they are convenient, stable, and precise dosing. For instance, in July 2021, according to the IDF Diabetes Atlas Tenth Edition 2021 report published by the International Diabetes Federation, a Belgium-based national diabetes association organization, the global number of people aged 20-78 years having diabetes is expected to reach 643 million by 2030, and 783 million by 2045 from 537 million in 2021. Therefore, the increasing prevalence of chronic diseases drives the growth of the oral solid dosage pharmaceutical formulation market.

Key Industry Players
Major companies operating in the oral solid dosage pharmaceutical formulation market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc., Novartis AG, Hoffman-La-Roche Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim GmbH, Gilead Sciences, Amgen Inc., Teva Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Biogen Inc., Lonza Group, Catalent Inc., Ashland Inc., Piramal Pharma Solutions, Jubilant Pharmova, CordenPharma International

The oral solid dosage pharmaceutical formulation market report table of contents includes:
1. Executive Summary
2. Oral Solid Dosage Pharmaceutical Formulation Market Characteristics
3. Oral Solid Dosage Pharmaceutical Formulation Market Trends And Strategies
4. Oral Solid Dosage Pharmaceutical Formulation Market - Macro Economic Scenario
5. Global Oral Solid Dosage Pharmaceutical Formulation Market Size and Growth
.
.
.
31. Global Oral Solid Dosage Pharmaceutical Formulation Market Competitive Benchmarking
32. Global Oral Solid Dosage Pharmaceutical Formulation Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Oral Solid Dosage Pharmaceutical Formulation Market
34. Oral Solid Dosage Pharmaceutical Formulation Market Future Outlook and Potential Analysis
35. Appendix